Replicative conditioning of Herpes simplex type 1 virus by Survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysis

Oncolytic virotherapy is emerging as a promising therapeutic option for solid tumours. Several oncolytic vectors in clinical testing are based on attenuated viruses; thus, efforts are being taken to develop a new repertoire of oncolytic viruses, based on virulent viral genomes. This possibility, how...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasso, Emanuele, Froechlich, Guendalina, Cotugno, Gabriella, D’Alise, Anna Morena, Gentile, Chiara, Bignone, Veronica, De Lucia, Maria, Petrovic, Biljana, Campadelli-Fiume, Gabriella, Scarselli, Elisa, Nicosia, Alfredo, Zambrano, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062820/
https://www.ncbi.nlm.nih.gov/pubmed/32152425
http://dx.doi.org/10.1038/s41598-020-61275-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062820/
https://www.ncbi.nlm.nih.gov/pubmed/32152425
http://dx.doi.org/10.1038/s41598-020-61275-w

Ejemplares similares